Aditxt, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
November 14, 2023 at 05:20 pm EST
Share
Aditxt, Inc. reported earnings results for the third quarter and nine months ended September 30, 2023. For the third quarter, the company reported sales was USD 0.124486 million compared to USD 0.323125 million a year ago. Net loss was USD 9.75 million compared to USD 7.56 million a year ago. Basic loss per share from continuing operations was USD 48.77 compared to USD 210.93 a year ago.
For the nine months, sales was USD 0.563879 million compared to USD 0.748119 million a year ago. Net loss was USD 21.41 million compared to USD 19.47 million a year ago. Basic loss per share from continuing operations was USD 136.94 compared to USD 720.54 a year ago.
Aditxt, Inc. is a biotech company focused on discovering, developing, and deploying health innovations. It develops and commercializes technologies with a focus on monitoring and modulating the immune system. Its portfolio includes Adimune, Inc., developing a new class of therapeutics designed to retrain the immune system to address organ rejection, autoimmunity, and allergies; Adivir, Inc., focused on identifying, developing, and commercializing new ways to treat infectious diseases, and Pearsanta, Inc., offering personalized lab testing, backed by CLIA-certified and CAP-accredited monitoring center. Adimune, Inc's immune modulation product candidate, ADI-100, is based on the Apoptotic DNA Immunotherapy platform technology, utilizes a novel approach that mimics the way bodies naturally induce tolerance to own tissues. It also offers electroencephalography (EEG) brain monitoring technologies and devices, including NeuroCap and NeuroEEG for telehealth and tele-neurology applications.
ADITXT, INC. 
